Current optimal chemotherapy for advanced urothelial cancer.
Conventional frontline cisplatin-based combination chemotherapy with gemcitabine and cisplatin, or traditional or dose-dense methotrexate, vinblastine, doxorubicin and cisplatin, yields high response rates but few durable remissions for advanced urothelial cancer. Salvage therapy is generally disappointing with few responses. A significant proportion of patients exhibit renal dysfunction, entailing carboplatin-based regimens that appear inferior to cisplatin-based regimens, which warrants a special focus In this population. The profusion of novel biologic agents offers the promise of improved outcomes. A multidisciplinary approach is necessary to make therapeutic advances.
Sonpavde
Guru
G
US Oncology Research & Texas Oncology PA, 501 Medical Center Blvd, Webster, TX 77598, USA. guru.sonpavde@usoncology.com
Galsky
Matthew D
MD
Hutson
Thomas E
TE
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary